Clinical trial
An Extension Study to Evaluate the Long-term Safety and Efficacy of Afimkibart (RO7790121) in Patients With Rheumatoid Arthritis Who Participated in Previous Afimkibart Clinical Trials
NCT07620392 is registered in ClinicalTrials.gov with Hoffmann-La Roche as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- An Extension Study to Evaluate the Long-term Safety and Efficacy of Afimkibart (RO7790121) in Patients With Rheumatoid Arthritis Who Participated in Previous Afimkibart Clinical Trials
- Lead sponsor
- Hoffmann-La Roche
- Phase
- Phase 2
- Overall status
- Recruiting
- Start date
- June 3, 2026
- Completion date
- July 8, 2033
- Enrollment
- 120 (estimated)
- Sites
- 10
Conditions
As the registry lists them; a condition with its own page is linked.
rheumatoid arthritis